Leukemic cells with increased telomerase activity exhibit resistance to imatinib

References

• Deininger M W, Goldman J M, Melo J V. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356
   PubMed Web of Science ®Google Scholar
• Konopka J B, Watanabe S M, Witte O N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035–1042
   PubMed Web of Science ®Google Scholar
• Melo J V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [comment]. Blood 1996; 88A: 2375–2384
   Google Scholar
• Daley G Q, Van Etten R A, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830
   PubMed Web of Science ®Google Scholar
• Scott M L, Van Etten R A, Daley G Q, Baltimore D. v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proceedings of the National Academy of Sciences of the United States of America 1991; 88: 6506–6510
   PubMed Web of Science ®Google Scholar
• Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia [comment]. N Engl J Med 2001; 344: 1031–1037
   PubMed Web of Science ®Google Scholar
• Blackburn E H. Structure and function of telomeres. Nature 1991; 350: 569–573
   PubMed Web of Science ®Google Scholar
• Kim N W, Piatyszek M A, Prowse K R, Harley C B, West M D, Ho P L, et al. Specific association of human telomerase activity with immortal cells and cancer [comment]. Science 1994; 266: 2011–2015
   PubMed Web of Science ®Google Scholar
• Lozzio C B, Lozzio B B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321–334
   PubMed Web of Science ®Google Scholar
• Rosenfeld C, Goutner A, Choquet C, Venuat A M, Kayibanda B, Pico J L, et al. Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature 1977; 267: 841–843
   PubMed Web of Science ®Google Scholar
• Namba M, Nishitani K, Hyodoh F, Fukushima F, Kimoto T. Neoplastic transformation of human diploid fibroblasts (KMST-6) by treatment with 60Co gamma rays. Int J Cancer 1985; 35: 275–280
   PubMed Web of Science ®Google Scholar
• Yamada O, Akiyama M, Kawauchi K, Adachi T, Yamada H, Kanda N, et al. Overexpression of telomerase confers a survival advantage through suppression of TRF1 gene expression while maintaining differentiation characteristics in K562 cells. Cell Transplant 2003; 12: 365–377
   Google Scholar
• Wick M, Zubov D, Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 1999; 232: 97–106
   PubMed Web of Science ®Google Scholar
• Akiyama M, Yamada O, Akita S, Urashima M, Horiguchi-Yamada J, Ohno T, et al. Ectopic expression of c-myc fails to overcome downregulation of telomerase activity induced by herbimycin A, but ectopic hTERT expression overcomes it. Leukemia 2000; 14: 1260–1265
   PubMed Web of Science ®Google Scholar
• Yamada O, Motoji T, Mizoguchi H. Up-regulation of telomerase activity in human lymphocytes. Biochim Biophys Acta 1996; 1314: 260–266
   PubMed Web of Science ®Google Scholar
• Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825–1832
   PubMed Web of Science ®Google Scholar
• Holt S E, Glinsky V V, Ivanova A B, Glinsky G V. Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinogen 1999; 25: 241–248
   PubMed Web of Science ®Google Scholar
• Fu W, Begley J G, Killen M W, Mattson M P. Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 1999; 274: 7264–7271
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang H, Bishop J M, Blackburn E H. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening [see Comment]. Proc Natl Acad Sci USA 1999; 96: 3723–3728
   PubMed Web of Science ®Google Scholar
• Kawauchi K, Ihjima K, Yamada O. IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3′-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J Immunol 2005; 174: 5261–5269
   PubMed Web of Science ®Google Scholar
• Tatematsu K, Nakayama J, Danbara M, Shionoya S, Sato H, Omine M, et al. A novel quantitative ‘stretch PCR assay’, that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias. Oncogene 1996; 13: 2265–2274
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin A S, La Rosee P, Muller M C, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196
   PubMed Web of Science ®Google Scholar
• Druker B J. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002; 21: 8541–8546
   PubMed Web of Science ®Google Scholar
• Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [comment]. Science 2001; 293: 876–880
   PubMed Web of Science ®Google Scholar
• Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321–1331
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Melo J V. The molecular biology of chronic myeloid leukaemia. Leukemia 1996; 10B: 751–756
   Google Scholar
• Sattler M, Salgia R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cyto Growth Factor Rev 1997; 8: 63–79
   PubMedGoogle Scholar
• Barnes D J, Palaiologou D, Panousopoulou E, Schultheis B, Yong A S, Wong A, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005; 65: 8912–8919
   PubMed Web of Science ®Google Scholar
• Donato N J, Wu J Y, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698
   PubMed Web of Science ®Google Scholar
• Martinelli G, Soverini S, Rosti G, Baccarani M. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 2005; 19: 1872–1879
   PubMed Web of Science ®Google Scholar
• Tauchi T, Ohyashiki K. The second generation of BCR-ABL tyrosine kinase inhibitors. Int J Hematol 2006; 83: 294–300
   PubMed Web of Science ®Google Scholar
• Stewart S A, Hahn W C, O'Connor B F, Banner E N, Lundberg A S, Modha P, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 2002; 99: 12606–12611
   PubMed Web of Science ®Google Scholar
• Akiyama M, Yamada O, Kanda N, Akita S, Kawano T, Ohno T, et al. Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett 2002; 178: 187–197
   Google Scholar
• Chen Z, Koeneman K S, Corey D R. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res 2003; 63: 5917–5925
   PubMed Web of Science ®Google Scholar
• Hofmann W K, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler H P, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study [comment]. Lancet 2002; 359: 481–486
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol 2005; 23: 6316–6324
   PubMed Web of Science ®Google Scholar
• Van Etten R A. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med 2007; 204: 461–465
   PubMed Web of Science ®Google Scholar